ECSP14013201A - Formulaciones parenterales de vacunas contra los norovirus - Google Patents

Formulaciones parenterales de vacunas contra los norovirus

Info

Publication number
ECSP14013201A
ECSP14013201A ECSP14013201A ECSP14013201A EC SP14013201 A ECSP14013201 A EC SP14013201A EC SP14013201 A ECSP14013201 A EC SP14013201A EC SP14013201 A ECSP14013201 A EC SP14013201A
Authority
EC
Ecuador
Prior art keywords
parenteral formulations
vaccines against
against norovirus
norovirus
compositions
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
Charles Richardson
Robert F Bargatze
Paul M Mendelman
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47506489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14013201(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of ECSP14013201A publication Critical patent/ECSP14013201A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
ECSP14013201 2011-07-11 2014-02-11 Formulaciones parenterales de vacunas contra los norovirus ECSP14013201A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161506447P 2011-07-11 2011-07-11

Publications (1)

Publication Number Publication Date
ECSP14013201A true ECSP14013201A (es) 2014-05-31

Family

ID=47506489

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP14013201 ECSP14013201A (es) 2011-07-11 2014-02-11 Formulaciones parenterales de vacunas contra los norovirus

Country Status (29)

Country Link
US (5) US9801934B2 (enExample)
EP (3) EP2731621B1 (enExample)
JP (2) JP6208659B2 (enExample)
KR (1) KR102096937B1 (enExample)
CN (3) CN108567975A (enExample)
AU (2) AU2012282658B2 (enExample)
BR (1) BR112014000656A2 (enExample)
CA (1) CA2841356C (enExample)
CL (1) CL2014000082A1 (enExample)
CR (2) CR20190540A (enExample)
DK (1) DK3299030T3 (enExample)
DO (2) DOP2014000004A (enExample)
EA (3) EA035442B1 (enExample)
EC (1) ECSP14013201A (enExample)
ES (2) ES2656527T3 (enExample)
GE (1) GEP201706668B (enExample)
HK (2) HK1199202A1 (enExample)
IL (1) IL230356B (enExample)
MA (1) MA35414B1 (enExample)
MX (2) MX356586B (enExample)
MY (1) MY170746A (enExample)
PE (1) PE20140845A1 (enExample)
PH (3) PH12014500093A1 (enExample)
PL (2) PL2731621T3 (enExample)
SG (1) SG10201605644WA (enExample)
TN (1) TN2014000008A1 (enExample)
UA (1) UA117732C2 (enExample)
WO (1) WO2013009849A1 (enExample)
ZA (2) ZA201401012B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2601969B1 (en) 2006-09-29 2016-03-30 Takeda Vaccines, Inc. Norovirus vaccine formulations
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
CN104740624B (zh) 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
PH12014500093A1 (en) 2011-07-11 2014-03-17 Takeda Vaccines Inc Parenteral norovirus vaccine formulations
JP2016533172A (ja) 2013-10-03 2016-10-27 タケダ ワクチン，インコーポレイテッド 細胞株からラブドウイルスを検出および除去する方法
WO2015093452A1 (ja) 2013-12-16 2015-06-25 武田薬品工業株式会社 マイクロニードル
CN107184970A (zh) * 2017-02-16 2017-09-22 北京生物制品研究所有限责任公司 口服诺如病毒亚单位疫苗及lt作为该疫苗佐剂的用途
GB201703644D0 (en) 2017-03-07 2017-04-19 Elopak As Improvements in or relating to toller mounting arrangements
EP3624851A1 (en) * 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
JP2021514391A (ja) * 2018-02-15 2021-06-10 アイコン ジェネティクス ゲーエムベーハー ノロウイルスに対する免疫応答を生成するための免疫原性組成物及びワクチン
WO2019231712A1 (en) * 2018-05-29 2019-12-05 Stc.Unm Virus-like particle compositions and methods of using same
CN109265542B (zh) * 2018-09-27 2021-06-15 国药中生生物技术研究院有限公司 特异性结合诺如病毒gii.4基因型vp1蛋白或vlp的抗体及其制备方法和应用
AR117462A1 (es) * 2018-12-20 2021-08-04 Takeda Vaccines Inc Vacuna contra norovirus, formulaciones y métodos
WO2021140524A1 (en) 2020-01-08 2021-07-15 Bharat Biotech International Limited Viral vaccine compositions and methods of preparations thereof
CN114685623A (zh) * 2020-12-30 2022-07-01 远大赛威信生命科学(南京)有限公司 Gii 2型诺如病毒的病毒样颗粒及其用途
WO2022210742A1 (ja) 2021-03-29 2022-10-06 デンカ株式会社 ノロウイルス由来のペプチド、ポリヌクレオチド、抗体、組成物、ノロウイルスの中和エピトープを同定する方法
WO2022246323A1 (en) 2021-05-21 2022-11-24 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial
CN118252924A (zh) * 2022-12-27 2024-06-28 远大赛威信生命科学(南京)有限公司 用于诱发哺乳动物针对诺如病毒的免疫反应的药物组合物及其制备方法和用途
WO2025077799A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Products Co., Ltd. Method of preparing norovirus vaccine without adjuvant
WO2025076792A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Product Co., Ltd. Methods of preparing norovirus vaccine with low amounts of adjuvant

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572862B1 (en) 1989-11-08 2003-06-03 Baylor College Of Medicine Methods and reagents to detect and characterize Norwalk and related viruses
AU1893592A (en) 1991-03-25 1992-10-21 Board Of Trustees Of The Leland Stanford Junior University Norwalk virus human gastroenteritis agent and molecular cloning of corresponding cdnas
AU683211B2 (en) 1992-04-08 1997-11-06 United States of America as represented by The Secretary Department of Health and Human Services, The Wild-type measles virus glycoproteins: vaccine and detection method therefor
WO1994005700A2 (en) 1992-09-07 1994-03-17 Baylor College Of Medicine Methods and reagents to detect and characterize norwalk and related viruses
KR100310510B1 (ko) 1993-03-23 2002-07-04 장 스테판느 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
US5788970A (en) 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
ES2264126T3 (es) 1994-05-16 2006-12-16 MERCK & CO., INC. Vacunas contra el papilomavirus.
US5645051A (en) 1995-04-21 1997-07-08 Dura Pharmaceuticals, Inc. Unit dose dry powder inhaler
US5861241A (en) 1995-08-16 1999-01-19 University Of Massachusetts Monoclonal antibodies for detecting Norwalk virus
GB9525083D0 (en) 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US5834015A (en) * 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
US5953727A (en) 1996-10-10 1999-09-14 Incyte Pharmaceuticals, Inc. Project-based full-length biomolecular sequence database
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
WO1998044944A2 (en) 1997-04-08 1998-10-15 Merck & Co., Inc. Stabilized human papillomavirus formulations
AU750702B2 (en) 1997-05-01 2002-07-25 Chiron Corporation Use of virus-like particles as adjuvants
US20040265377A1 (en) 1997-10-27 2004-12-30 Harry Seager Solid dispersing vaccine composition for oral delivery
EP1105466B1 (en) 1998-08-14 2006-04-26 Merck & Co., Inc. Process for purifying human papillomavirus virus-like particles
CA2354444A1 (en) 1998-12-17 2000-06-22 Merck & Co., Inc. Synthetic virus-like particles with heterologous epitopes
ATE413188T1 (de) * 1999-02-05 2008-11-15 Merck & Co Inc Menschliche papillomavirus impfstoff- formulierungen
CA2375337C (en) 1999-06-22 2012-09-25 Naokazu Takeda Srsv detection kit
JP2002020399A (ja) 2000-07-10 2002-01-23 Osaka Prefecture ノルウォークウイルス（ｎｖ）を認識するモノクローナル抗体
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
WO2003068804A2 (en) 2002-02-14 2003-08-21 Novavax, Inc. Novel insect cell line
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
EP1494651A4 (en) 2002-04-11 2010-10-13 Medimmune Vaccines Inc PRESERVATION OF BIOACTIVE MATERIALS WITH FREEZZED FOAM
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
JP2006507800A (ja) 2002-06-07 2006-03-09 ラージ・スケール・バイオロジー・コーポレイション 可撓性ワクチンアセンブリおよびワクチン送達プラットフォーム
ATE489969T1 (de) 2002-06-20 2010-12-15 Cytos Biotechnology Ag Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung
CA2514667C (en) 2003-01-30 2013-01-08 Chiron Corporation Adjuvanted influenza vaccine
WO2004073652A2 (en) 2003-02-20 2004-09-02 Becton Dickinson And Company Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US7879338B2 (en) 2003-07-21 2011-02-01 Boyce Thompson Institute For Plant Research Vectors and methods for immunization against norovirus using transgenic plants
JP2007537137A (ja) 2003-09-24 2007-12-20 モンタナ ステート ユニバーシティ ノロウィルスモノクローナル抗体及びペプチド
WO2005037223A2 (en) 2003-10-15 2005-04-28 Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
US20050215501A1 (en) 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
FR2863890B1 (fr) 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US20050260225A1 (en) 2004-05-18 2005-11-24 Goldberg Joanna B Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens
CU23496A1 (es) 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
SG156666A1 (en) 2004-10-20 2009-11-26 Acambis Inc Vaccines against japanese encephalitis virus and west nile virus
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
WO2006074303A2 (en) 2005-01-05 2006-07-13 Philadelphia Health And Education Corporation Delivery vehicles, bioactive substances and viral vaccines
US8168771B2 (en) 2005-01-31 2012-05-01 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
ES2424229T3 (es) 2005-03-18 2013-09-30 Cytos Biotechnology Ag Proteínas de fusión de alérgenos de gato y utilización de las mismas
CA2608515A1 (en) 2005-06-01 2007-05-10 Dow Global Technolgies Inc. Production of multivalent virus like particles
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
JP2007145775A (ja) 2005-11-29 2007-06-14 Falco Life Science:Kk ノロウイルスｇｉの高感度検出方法
US20080029915A1 (en) * 2006-08-02 2008-02-07 Courtoy Nv Rotary tablet press
EP2601969B1 (en) * 2006-09-29 2016-03-30 Takeda Vaccines, Inc. Norovirus vaccine formulations
JP2011506264A (ja) 2006-12-06 2011-03-03 ノバルティス アーゲー インフルエンザウイルスの４つの株に由来する抗原を含むワクチン
CA2683977C (en) * 2007-03-14 2017-04-25 Ligocyte Pharmaceuticals, Inc. A method of norovirus virus-like particle purification comprising ion exchange chromatography
WO2009033229A1 (en) 2007-09-12 2009-03-19 Australian Centre For Plant Functional Genomics Pty Ltd Plant seed active transcriptional control sequences
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
CN104740624B (zh) * 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
JP5852883B2 (ja) 2008-08-08 2016-02-03 タケダ ワクチン，インコーポレイテッド 交差反応性の増強のための複合カプシドアミノ酸配列を含むウイルス様粒子
CA2750321A1 (en) * 2009-01-22 2010-07-29 Pharmathene, Inc. Stable vaccine compositions and methods of use
WO2010092476A1 (en) * 2009-02-10 2010-08-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
US20110070260A1 (en) 2009-09-09 2011-03-24 Baric Ralph S Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
JP2013517773A (ja) 2010-01-21 2013-05-20 リゴサイト ファーマスーティカルズ，インコーポレイテッド カリシウイルスウイルス様粒子上の標的化異種抗原提示
CN107029223A (zh) * 2010-05-26 2017-08-11 西莱克塔生物科技公司 合成纳米载体联合疫苗
PH12014500093A1 (en) 2011-07-11 2014-03-17 Takeda Vaccines Inc Parenteral norovirus vaccine formulations
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
AU2016374497B2 (en) 2015-12-16 2022-03-10 The Walter And Eliza Hall Institute Of Medical Research Inhibition of cytokine-induced SH2 protein in NK cells
EP4338799A3 (en) 2016-10-18 2024-06-05 Regents of the University of Minnesota Tumor infiltrating lymphocytes and methods of therapy
SG11202010763VA (en) 2018-05-03 2020-11-27 Univ Texas Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade
JP2021534074A (ja) 2018-08-20 2021-12-09 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. Ｖｌｐ製剤
AR117462A1 (es) 2018-12-20 2021-08-04 Takeda Vaccines Inc Vacuna contra norovirus, formulaciones y métodos
BR112021016046A2 (pt) 2019-02-15 2021-11-09 Editas Medicine Inc Células assassinas naturais modificadas (nk) para imunoterapia

Also Published As

Publication number Publication date
NZ620865A (en) 2015-08-28
DOP2014000004A (es) 2014-10-31
US10675341B2 (en) 2020-06-09
PL2731621T3 (pl) 2018-10-31
CA2841356C (en) 2022-03-01
MX356586B (es) 2018-06-05
BR112014000656A2 (pt) 2017-02-14
US20210085778A1 (en) 2021-03-25
EP4112074A1 (en) 2023-01-04
MA35414B1 (fr) 2014-09-01
DK3299030T3 (da) 2022-09-05
CR20140069A (es) 2014-06-27
HK1198136A1 (en) 2015-03-13
EP2731621A1 (en) 2014-05-21
PL3299030T3 (pl) 2022-12-05
DOP2022000030A (es) 2022-06-30
EP2731621B1 (en) 2017-11-01
EA202090699A3 (ru) 2020-11-30
EA029470B1 (ru) 2018-03-30
US11701420B2 (en) 2023-07-18
JP2017214357A (ja) 2017-12-07
EA035442B1 (ru) 2020-06-17
EP2731621A4 (en) 2015-03-25
ES2926487T3 (es) 2022-10-26
AU2012282658A1 (en) 2013-03-14
US9801934B2 (en) 2017-10-31
IL230356B (en) 2019-05-30
AU2015200836B2 (en) 2016-08-25
US20230338503A1 (en) 2023-10-26
CN105031637A (zh) 2015-11-11
EA201490258A1 (ru) 2014-05-30
AU2015200836A1 (en) 2015-03-12
PH12018501515B1 (en) 2022-02-18
JP2014520852A (ja) 2014-08-25
US20180185468A1 (en) 2018-07-05
NZ710919A (en) 2017-12-22
PH12018501515A1 (en) 2019-02-04
SG10201605644WA (en) 2016-09-29
TN2014000008A1 (en) 2015-07-01
CL2014000082A1 (es) 2014-07-04
PH12021551773A1 (en) 2022-08-01
ZA201500915B (en) 2016-06-29
HK1199202A1 (en) 2015-06-26
CN103874507A (zh) 2014-06-18
HK1215154A1 (zh) 2016-08-19
WO2013009849A1 (en) 2013-01-17
CR20190540A (es) 2022-04-04
CA2841356A1 (en) 2013-01-17
JP6613259B2 (ja) 2019-11-27
EP3299030B1 (en) 2022-06-08
MX2014000411A (es) 2014-08-26
EP3299030A1 (en) 2018-03-28
US9867876B2 (en) 2018-01-16
EA201792407A3 (ru) 2018-07-31
ES2656527T3 (es) 2018-02-27
AU2012282658B2 (en) 2014-11-27
KR102096937B1 (ko) 2020-04-03
US20160000899A1 (en) 2016-01-07
US20130273102A1 (en) 2013-10-17
ZA201401012B (en) 2015-05-27
GEP201706668B (en) 2017-05-25
KR20140066160A (ko) 2014-05-30
MX379496B (es) 2025-03-11
EA201792407A2 (ru) 2018-03-30
JP6208659B2 (ja) 2017-10-04
EA202090699A2 (ru) 2020-07-31
PE20140845A1 (es) 2014-08-03
PH12014500093A1 (en) 2014-03-17
MY170746A (en) 2019-08-27
UA117732C2 (uk) 2018-09-25
CN108567975A (zh) 2018-09-25

Similar Documents

Publication Publication Date Title
DOP2014000004A (es) Formulaciones parenterales de vacunas contra los norovirus
MX383065B (es) Mutantes de virus de influenza y usos para los mismos.
MX2015010880A (es) Combinacion de vacunacion e inhibicion de la trayectoria pd-1.
MX2018002728A (es) Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas.
AR133161A2 (es) Vacunas de partículas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos
PE20151588A1 (es) Vacuna contra el virus del dengue
MX342716B (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
MX347210B (es) Vacunas combinadas para prevención de infecciones por virus porcino.
EA201391515A1 (ru) Инактивированная вакцина вируса денге
CO6561819A2 (es) Vectores para vacunas y método para potenciar respuestas inmunes
MY168959A (en) Vaccine compositions for the prevention of dengue virus infection
PH12014502875A1 (en) Vaccine compositions for prevention against dengue virus infection
EP2825196A4 (en) ADJUVANZ AND VACCINE COMPOSITIONS
MX2017005687A (es) Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
BR112015021523A2 (pt) composição de uma vacina contra a tosse convulsa acelular, e, métodos para vacinar um sujeito contra a bordetella pertussis e para proteger um sujeito da tosse convulsa
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
BR112015002549A2 (pt) regime de vacinação para proteger uma criança contra infecção ou doença causada por vírus sincicial respiratório, composição imunogênica ou pluralidade de composições imunogênicas, uso de uma composição imunogênica ou de uma pluralidade de composições imunogênicas
WO2013033496A3 (en) Laser adjuvants for enhancing immune response
MX2016002823A (es) Metodos y composiciones para vacunas vectorizadas virales.
UY38933A (es) Vacuna de partículas tipo virus del chicunguña y métodos para su uso
GT201400120A (es) Procedimiento de formulación de una vacuna que contiene al menos dos antígenos susceptibles de adsorberse en oxihidróxido de aluminio
BR112012022680A2 (pt) métodos para proteger um animal um canino contra doença, e, uso de uma vacina contra vírus da influenza canina
IN2014MN02275A (enExample)
UY35329A (es) Composición farmacéutica para administración oral que comprende fexofenadina y proceso para preparar la misma.